BusinessGenticel Reports Initial Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001By Nasdaq OMXJan 27, 2016, 6:23 PM UTC
BusinessGenticel to Evaluate Roche Molecular Systems’ cobas® HPV Test in Preparation for Phase 3 Program of GTL001By Nasdaq OMXJan 7, 2016, 1:00 PM UTC
